IRVING, Texas, June 13 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN - News) today announced that it has received a European patent which describes composition and method for stabilization and delivery of growth factors and cytokines with the Company's proprietary GelSite® Polymer. This patent expands the proprietary base of the Company's drug and vaccine delivery technologies. DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, has completed a Phase I human safety study of the GelVac(TM) nasal vaccine delivery system and is actively preparing to initiate clinical trials with influenza (flu) antigen.
